iTonic Holdings Ltd Issues an Update on its Effort to Develop AI-Powered Cloud Healthcare Platform Designed to Support Nuclear Medicine Treatment Planning and with Potential Future Expansion into Digital Care Delivery
Rhea-AI Summary
iTonic Holdings (Nasdaq: ITOC) provided an update on its AI-enabled Treatment Planning System (TPS) Cloud Platform being developed via 60%-owned Mili Medical to support nuclear medicine and radiation treatment planning. The browser-based platform is intended to integrate AI-assisted planning, automated quality control, and standardized data management for multi-location hospital networks.
According to the company, current milestones include core cloud architecture, browser TPS, data-sharing framework, initial AI model training, and quality-control rules. The system is undergoing internal testing and clinical workflow validation, has not been clinically validated or approved by regulators, and is expected to be regulated as medical device software in China.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ITOC
On the day this news was published, ITOC declined 2.29%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.8% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $897K from the company's valuation, bringing the market cap to $38.26M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Nasdaq compliance extension | Positive | +24.8% | Nasdaq granted 180‑day extension to regain minimum bid price compliance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history: one recent Nasdaq compliance extension headline saw a strongly positive next‑day price reaction.
Key Terms
artificial intelligence technical
nuclear medicine medical
clinical workflow validation medical
medical device software regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
New cloud-based platform is being developed to integrate artificial intelligence, automated quality control and healthcare data connectivity to support next-generation precision medicine workflows.
Beijing, China, July 15, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (Nasdaq: ITOC) (the “Company”), a technology-driven healthcare company focused on developing innovative digital medical solutions, today announced continued progress in the development of its next-generation AI-enabled Treatment Planning System (“TPS”) Cloud Platform through Mili (Jiangsu) Medical Technology Co., Ltd. (“Mili Medical”), a technology company focused on digital solutions for nuclear medicine and radiation treatment planning. The Company, through its indirect PRC subsidiary, has held a
The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence (“AI”), medical data connectivity, automated quality control and workflow management capabilities.
The Company is seeking to address the increasing focus on digital transformation, precision medicine and intelligent healthcare workflows by enabling hospitals and medical institutions to improve treatment efficiency, standardize clinical workflows and enhance patient care coordination.
Key Highlights
● Cloud-Based Transformation of Treatment Planning Software
Mili Medical is upgrading, with support from the Company, its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations.
● AI-Assisted Treatment Planning Under Development
The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review.
● Integrated Quality Control and Data Management
The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process.
● Designed for Hospital Networks and Digital Healthcare Ecosystems
The modular cloud architecture is designed to support future expansion into additional healthcare applications, including medical data management, supply chain coordination, research collaboration and intelligent healthcare services.
● Transforming Traditional Healthcare Workflows Through Cloud and AI Technology
Traditional treatment planning systems are typically deployed as standalone applications requiring local installation and independent operation within individual departments. The Company believes this approach may limit data sharing, workflow collaboration and scalability across healthcare networks.
Current Development Status
As of the date of this announcement, the Company has completed significant development milestones, including:
- Core cloud architecture development;
- Browser-based TPS functionality development;
- Medical data sharing framework development;
- Initial AI model training;
- Quality control rule framework development.
The Company is currently conducting internal testing, system optimization and clinical workflow validation. The platform has not been clinically validated for commercial use and has not received registration, clearance or approval from applicable regulators. The Company continues to evaluate collaboration opportunities with healthcare institutions to support future commercialization and market deployment.
The TPS Cloud Platform is being developed by the Company to address these limitations by creating a centralized digital environment that connects physicians, medical departments and healthcare institutions through secure cloud-based workflows.
The platform is expected to provide:
- Browser-based treatment planning access;
- Multi-location collaboration capabilities;
- Standardized medical data management;
- Automated workflow monitoring;
- Enhanced treatment planning efficiency.
AI Technology Designed to Enhance Precision Medicine
A core component of the platform is the integration of artificial intelligence technology designed to support clinical decision-making.
The AI module is being developed to assist with:
- Automated identification and segmentation of treatment areas;
- Intelligent treatment plan recommendations;
- Continuous algorithm improvement through clinical data feedback;
- Reduction of repetitive manual processes.
The Company expects AI-assisted workflows may help healthcare professionals improve operational efficiency while maintaining physician oversight and clinical decision-making.
Automated Quality Control and Healthcare Data Integration
The Company is also developing a comprehensive quality control module intended to create a digital monitoring framework covering key treatment planning processes.
Potential capabilities include:
- Treatment plan verification;
- Automated quality checks;
- Data recording and traceability;
- Exception alerts and reporting;
- Integration with existing hospital information systems.
The Company believes these capabilities may support healthcare institutions seeking greater standardization, transparency and compliance in clinical operations if successfully developed and implemented.
Expanding Toward a Broader Digital Healthcare Ecosystem
Following completion and validation of the core cloud platform, the Company plans to explore additional modular applications, including:
- Healthcare supply chain management: Digital tracking and management of medical supplies and equipment;
- Nuclear medicine management: Supporting lifecycle tracking of nuclear medicine materials and related records;
- Medical robotics integration: Potential connection between treatment planning systems and advanced medical equipment;
- Clinical research and patient management tools: Supporting research collaboration and long-term patient data management.
Regulatory Status
The TPS Cloud Platform is expected to be regulated as medical device software in China and remains subject to applicable regulatory requirements, including registration testing, registration application and review procedures. The platform has not received regulatory approval or registration for commercialization, and there can be no assurance as to the timing or outcome of any required registration or approval process. Any delay in completing applicable regulatory procedures could delay the platform’s commercialization and market deployment.
“Healthcare is undergoing a significant digital transformation driven by artificial intelligence, cloud computing and data connectivity,” said Jianfei Zhang, Chief Executive Officer of iTonic Holdings Ltd. “We believe our AI-powered TPS Cloud Platform represents an important step toward building a more connected and intelligent healthcare ecosystem. By combining treatment planning technology, AI assistance and digital workflow management, we aim to support healthcare providers in delivering more efficient and precise patient care.”
About Mili (Jiangsu) Medical Technology Co., Ltd.
Mili (Jiangsu) Medical Technology Co., Ltd. focuses on the research, development and commercialization of digital healthcare technologies, including nuclear medicine treatment planning software and related medical technology solutions. The company’s technology initiatives focus on improving healthcare digitization, treatment workflow efficiency and clinical data management through software innovation.
About iTonic Holdings Ltd
iTonic Holdings Ltd (Nasdaq: ITOC) is a technology-driven healthcare company focused on developing innovative digital medical solutions. Through strategic investments and technology partnerships, the Company seeks to advance healthcare transformation through artificial intelligence, automation and intelligent data platforms.
For more information, please visit: http://www.ftzy.com.cn/ir/overview.php
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. federal securities laws. Forward-looking statements can be identified by words such as “believes,” “expects,” “plans,” “designed,” “intended,” “potential,” “may,” “could,” “aims” and similar expressions. Forward-looking statements include statements regarding the anticipated development, testing, validation, regulatory review, registration or approval, commercialization, market opportunities, benefits and future performance of the Company’s AI-powered TPS Cloud Platform and related healthcare technologies.
These statements are based on current expectations and assumptions and involve risks and uncertainties, including, but not limited to, the TPS Cloud Platform may not be completed on the expected timeline or at all; AI model performance may not meet expectations; internal testing, system optimization, clinical workflow validation or hospital integration may identify technical, operational, data-security, privacy, regulatory or clinical issues; Mili Medical and/or the Company may be unable to obtain required medical-device software registration, clearance or approval in China or other markets; regulatory review may be delayed or result in additional requirements; the platform may not be commercially deployed or accepted by healthcare institutions; collaborations, suppliers, counterparties or data sources may not be available on acceptable terms; the Company may not have sufficient financing or working capital to complete development or commercialization; and competitive, market, regulatory and other risks may affect the platform and the Company’s business.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.
Investor Relations Contact:
iTonic Holdings Ltd
Investor Relations
Email: ir@ftzy.com.cn
LLYC
Jackson Lin
Phone: +1-646-717-4593
Email: jian.lin@llyc.global
